The efficacy of topical tazarotene monotherapy and combination therapies in psoriasis

Koo, John; Behnam, Shahdad E

doi:10.1517/14656566.4.12.2347

Cited by 9 publications

(4 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Itch is the most bothersome skin symptom in patients with psoriasis, with around 75% regarding freedom from itch as a primary need . Furthermore, itch itself can be exacerbated by psoriasis therapies, such as tazarotene and phototherapy . Psoriasis‐related itch has a significant impact on patients’ lives, adversely affecting health‐related quality of life (HRQoL) and sleep, and can lead to feelings of stigmatisation, as well as stress and depressive symptoms …”

Section: Introductionmentioning

confidence: 99%

Itch relief in patients with psoriasis: effectiveness of calcipotriol plus betamethasone dipropionate foam

Jalili¹,

Lebwohl

Gold

et al. 2019

Acad Dermatol Venereol

View full text Add to dashboard Cite

Background Itch is common in psoriasis, adversely affecting health-related quality of life (HRQoL) and sleep.Objective We evaluated the efficacy of topical fixed-dose combination calcipotriol 50 lg/g plus betamethasone dipropionate 0.5 mg/g cutaneous foam (Cal/BD foam) on itch, itch-related sleep loss and HRQoL vs. foam vehicle. Methods We pooled data from three Phase II/III trials (NCT01536886/NCT01866163/NCT02132936) of Cal/BD foam vs. foam vehicle in adults with mild-severe psoriasis. For itch-related analyses, patients with baseline itch visual analogue scale (VAS) >40 (range 0-100) were analysed. Outcomes included the following: itch VAS reduction >40, ≥70% improvement in itch (Itch70) or itch-related sleep loss, 75% improvement in modified Psoriasis Area and Severity Index (excluding head; mPASI75) and Dermatology Life Quality Index (DLQI) scores 0/1 through 4 weeks. ResultsOf 837 patients, 800 had baseline itch VAS >0 (Cal/BD foam, n = 610; foam vehicle, n = 190); 484 had baseline itch VAS >40. There was no correlation between itch VAS score and mPASI at baseline (R 2 = 0.021). In patients with baseline itch VAS >40, more patients achieved itch VAS reduction >40 in the active vs. vehicle group from Day 5 onwards (Day 5: 57.5% vs. 40.2% [P < 0.05]; Week 4: 83.0% vs. 45.8% [P < 0.001]). More Cal/BD-foam-treated patients achieved Itch70 at Day 3 (34.2% vs. 22.5%; P < 0.05) through to Week 4 (79.3% vs. 38.1%; P < 0.001). In patients with baseline itch VAS >40 and sleep loss >20, improvements in itch-related sleep loss occurred at Week 1 and continued through 4 weeks. Itch-related improvements occurred before improvements in mPASI75. There were significant differences in the proportion of Cal/BD-foam-vs. foam-vehicle-treated patients with baseline DLQI >10 (n = 172 vs. n = 50) achieving DLQI ≤1 (25.0% vs. 4.0%; P = 0.001) and DLQI 0 (17.4% vs. 2.0%; P = 0.006) at Week 4.Conclusion Compared with foam vehicle, Cal/BD foam offers more rapid and effective itch relief, with associated significant improvements in sleep and DLQI. are employees of LEO Pharma A/S. Funding sourceThis study was sponsored by LEO Pharma.This manuscript contains original unpublished work and has not been submitted for publication elsewhere. Some of these data have previously been presented in poster format at the 27th European Academy of Dermatology and Venereology Congress 2018 (P2016).JEADV 2019, 33, 709-717 710 Jalili et al.

show abstract

Section: Introductionmentioning

confidence: 99%

Itch relief in patients with psoriasis: effectiveness of calcipotriol plus betamethasone dipropionate foam

Jalili¹,

Lebwohl

Gold

et al. 2019

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…Some synthetic retinoids, such as 36 (adapalene), 37 (tazalotene), and 4 (Figure 11), have been proven to be clinically useful in the treatment of acne and psoriasis. 7,60,61 The most successful clinical application of retinoids is ATRA therapy of APL. 62,63 More than 90% of APL patients achieved complete remission (CR) with ATRA treatment.…”

Section: Prospects For Retinoid Therapymentioning

confidence: 99%

“…Retinoid therapy using synthetic retinoids has already been realized in the fields of dermatology and oncology. Some synthetic retinoids, such as 36 (adapalene), 37 (tazalotene), and 4 (Figure ), have been proven to be clinically useful in the treatment of acne and psoriasis. ,, The most successful clinical application of retinoids is ATRA therapy of APL. , More than 90% of APL patients achieved complete remission (CR) with ATRA treatment. ATRA is less effective in APL patients who relapsed after complete remission induced by ATRA (less than 20% CR), while a synthetic retinoid, 4 , was shown to be effective (about 60% CR) in such patients …”

Section: Prospects For Retinoid Therapymentioning

confidence: 99%

Synthetic Retinoids: Recent Developments Concerning Structure and Clinical Utility

2005

View full text Add to dashboard Cite

“…Tazarotene is converted to tazarotenic acid in presence of esterases in the skin, both tazarotene and tazarotenic acid have a selective affinity towards retinoic acid receptors γ and β. It is insoluble in water (0.00075 mg/mL) and has p K a of 1.23 .…”

Section: Introductionmentioning

confidence: 99%

Stability indicating liquid chromatographic method for simultaneous quantification of betamethasone valerate and tazarotene in in vitro and ex vivo studies of complex nanoformulation

Rapalli

Singhvi

Gorantla

et al. 2019

J of Separation Science

View full text Add to dashboard Cite

Low‐potency corticosteroid betamethasone valerate and vitamin‐A tazarotene are used in combination for effective treatment of psoriasis. There is no robust high‐performance liquid chromatography analytical technique available for simultaneous estimation of betamethasone valerate and tazarotene in conventional and nanocarriers based formulations. A simple, accurate, robust isocratic high‐performance liquid chromatography method was developed for simultaneous estimation of betamethasone valerate and tazarotene in topical pharmaceutical formulations. The developed method was validated as per the regulatory guidelines. The validated method was linear over the concentration range of 150–6000 ng/mL (r2 > 0.999) at 239 nm wavelength. Limits of detection and quantification of two analytes were 50 and 150 ng/mL, respectively. The %relative standard deviation for intraday and interday precision was less than 2%. The method was also evaluated in the presence of forced degradation conditions. The developed method was successfully applied for in vitro and ex vivo drug release studies of in‐house designed nanoformulations.

show abstract

The efficacy of topical tazarotene monotherapy and combination therapies in psoriasis

Cited by 9 publications

References 36 publications

Itch relief in patients with psoriasis: effectiveness of calcipotriol plus betamethasone dipropionate foam

Itch relief in patients with psoriasis: effectiveness of calcipotriol plus betamethasone dipropionate foam

Synthetic Retinoids: Recent Developments Concerning Structure and Clinical Utility

Stability indicating liquid chromatographic method for simultaneous quantification of betamethasone valerate and tazarotene in in vitro and ex vivo studies of complex nanoformulation

Contact Info

Product

Resources

About